Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | HK2 | P52789 | 5/20 | 0.52 |
| ▸ | HK1 | P19367 | 4/20 | 0.52 |
| ▸ | PYGB | P11216 | 7/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18467702 | 1.00 | LMNA (0.57) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| SCHEMBL15966274 | 1.00 | LMNA (0.57) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| SCHEMBL12190147 | 1.00 | LMNA (0.57) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| SCHEMBL15965658 | 1.00 | LMNA (0.57) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| SCHEMBL29532523 | 1.00 | LMNA (0.57) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| N-Acetylglucosamine SCHEMBL19423349 | 0.92 | MAPK1 (0.56) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| SCHEMBL24252744 | 0.86 | KDM4E (0.55) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| SCHEMBL24141320 | 0.86 | LMNA (0.55) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| SCHEMBL14520983 | 0.86 | LMNA (0.55) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| SCHEMBL23880301 | 0.86 | PYGB (0.64) | LMNAKDM4ECYP2D6CYP2C19HK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250275993-A1 | GLYCOSYLATION INHIBITORS AS THERAPEUTICS FOR STROKE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-09-04 | — | — | US | disclosed |
| CN-119300837-A | Glycosylation inhibitors as therapeutic agents for stroke | 加利福尼亚大学董事会 | 2025-01-10 | — | — | CN | disclosed |
| US-20240084352-A1 | MICROBIAL POLYSACCHARIDES AND METHODS OF USE | MORGAN STATE UNIV (US) | 2024-03-14 | — | — | US | disclosed |
| US-20200332335-A1 | MICROBIAL POLYSACCHARIDES AND METHODS OF USE | MORGAN STATE UNIVERSITY | 2020-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240084352-A1 | MICROBIAL POLYSACCHARIDES AND METHODS OF USE | NANS, GMDS, SIGLEC7 | LMNA 1866/4885KDM4E 4621/4885CYP2D6 3346/4885 |
| US-20200332335-A1 | MICROBIAL POLYSACCHARIDES AND METHODS OF USE | NANS, GMDS, SIGLEC7 | LMNA 1866/4885KDM4E 4621/4885CYP2D6 3346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.